Skip to main content

Search Videos and More

Showing 25 - 34 of 34 results

Previous| 1 | 2 | 3 |Next

From a lipid specialist’s perspective, do the results from the ODYSSEY Outcomes Trial suggest the need to be more focused on achieving absolute target levels of LDL-C or relative percentage reductions in LDL-C levels?

From a lipid specialist’s perspective, do the results from the ODYSSEY Outcomes Trial suggest the need to be more focused on achieving absolute target levels of LDL-C or relative percentage reductions in LDL-C levels?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

IC and lipid specialists are challenged to maximize CV risk reduction in high-risk populations. How should they approach the 70 mg/dL LDL-C target identified in the AHA Guidelines, and when is the 30 mg/dL – 70 mg/dL even more desirable?

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

What other markers, besides LDL-C levels, do you believe we should consider to refine CV risk stratification?

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

Representing the landscapes of IC and atherosclerosis prevention/lipid management, How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

Representing the landscapes of IC and atherosclerosis prevention/lipid management, How do you identify “progressing patients” with high CV risk in whom PCSK9 therapy represents a game-changing strategy?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

You have introduced the concept of progressive atherosclerotic burden to characterize the multiplicity of biologic, metabolic & clinical markers in a CV risk profile. How do you apply this “aggregated risk” to patient selection for PCSK9 inhibitors?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

Do you use different LDL-C levels in persons with diabetes to justify initiation of PCSK9 inhibitors? Is the presence of ACS required or symptomatic ASCVD required to triage them into PCSK9-based treatment?

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL?

In your mind, as a Director of a Lipid Clinic and Preventive Cardiology Center, how do you apply the results of the ODYSSEY Outcomes and other trials in terms of the lack of safety signals when lowering LDL-C to levels < 50 mg/dL?

Showing 25 - 34 of 34 results

Previous| 1 | 2 | 3 |Next